Published in J Tradit Complement Med on January 01, 2014
Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable Angina (CAESA) | NCT01659580
Herbal hepatotoxicity in traditional and modern medicine: actual key issues and new encouraging steps. Front Pharmacol (2015) 1.04
Herbal traditional Chinese medicine and its evidence base in gastrointestinal disorders. World J Gastroenterol (2015) 0.98
Herbal Hepatotoxicity: Clinical Characteristics and Listing Compilation. Int J Mol Sci (2016) 0.82
Safety surveillance of traditional Chinese medicine: current and future. Drug Saf (2015) 0.80
Botanicals and Their Bioactive Phytochemicals for Women's Health. Pharmacol Rev (2016) 0.78
New Exploration of Chinese Herbal Medicines in Hepatology. Evid Based Complement Alternat Med (2016) 0.75
Traditional Chinese Medicine (TCM) and Herbal Hepatotoxicity: RUCAM and the Role of Novel Diagnostic Biomarkers Such as MicroRNAs. Medicines (Basel) (2016) 0.75
Ashtawarga plants - Suffering a triple standardization syndrome. J Tradit Complement Med (2017) 0.75
Network medicine: a network-based approach to human disease. Nat Rev Genet (2011) 14.07
Predicting new molecular targets for known drugs. Nature (2009) 9.71
Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol (2008) 8.51
How were new medicines discovered? Nat Rev Drug Discov (2011) 7.00
Molecular networks as sensors and drivers of common human diseases. Nature (2009) 6.14
Asian medicine. The new face of traditional Chinese medicine. Science (2003) 5.12
Global mapping of pharmacological space. Nat Biotechnol (2006) 4.99
The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity. Sci Transl Med (2010) 4.78
Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci U S A (2008) 3.71
Molecular understanding and modern application of traditional medicines: triumphs and trials. Cell (2007) 2.51
Can we rationally design promiscuous drugs? Curr Opin Struct Biol (2006) 2.06
Modulating angiogenesis: the yin and the yang in ginseng. Circulation (2004) 1.86
Systems biology guided by Chinese medicine reveals new markers for sub-typing rheumatoid arthritis patients. J Clin Rheumatol (2009) 1.64
Red ginseng for treating erectile dysfunction: a systematic review. Br J Clin Pharmacol (2008) 1.59
Innovation: Rescuing drug discovery: in vivo systems pathology and systems pharmacology. Nat Rev Drug Discov (2005) 1.52
A comprehensive platform for quality control of botanical drugs (PhytomicsQC): a case study of Huangqin Tang (HQT) and PHY906. Chin Med (2010) 1.39
The angiogenic effects of Angelica sinensis extract on HUVEC in vitro and zebrafish in vivo. J Cell Biochem (2008) 1.34
The chemical basis of pharmacology. Biochemistry (2010) 1.30
Angiogenesis: from plants to blood vessels. Trends Pharmacol Sci (2006) 1.28
The natural compound n-butylidenephthalide derived from the volatile oil of Radix Angelica sinensis inhibits angiogenesis in vitro and in vivo. Angiogenesis (2011) 1.20
In vitro anti-fibrotic activities of herbal compounds and herbs. Nephrol Dial Transplant (2009) 1.18
Integrated omics approaches in plant systems biology. Curr Opin Chem Biol (2009) 1.17
Ginsenoside Rb1 inhibits tube-like structure formation of endothelial cells by regulating pigment epithelium-derived factor through the oestrogen beta receptor. Br J Pharmacol (2007) 1.16
Signaling pathway of ginsenoside-Rg1 leading to nitric oxide production in endothelial cells. FEBS Lett (2006) 1.15
Quality, efficacy and safety of complementary medicines: fashions, facts and the future. Part I. Regulation and quality. Br J Clin Pharmacol (2003) 1.12
Guidelines for randomised controlled trials investigating Chinese herbal medicine. J Ethnopharmacol (2011) 1.09
Advances in shotgun proteomics and the analysis of membrane proteomes. J Proteomics (2010) 1.08
Herb-drug interactions: an overview of systematic reviews. Br J Clin Pharmacol (2013) 1.06
Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma. Anticancer Res (2009) 1.00
New therapies from old medicines. Nat Biotechnol (2008) 0.99
Herbal hepatotoxicity: a critical review. Br J Clin Pharmacol (2013) 0.99
The effect of St John's wort extracts on CYP3A: a systematic review of prospective clinical trials. Br J Clin Pharmacol (2006) 0.98
Future development of global regulations of Chinese herbal products. J Ethnopharmacol (2012) 0.96
The rise of traditional Chinese medicine and its materia medica: a comparison of the frequency and safety of materials and species used in Europe and China. J Ethnopharmacol (2013) 0.94
Chemogenomics approaches to rationalizing the mode-of-action of traditional Chinese and Ayurvedic medicines. J Chem Inf Model (2013) 0.93
Anticancer activity of Amauroderma rude. PLoS One (2013) 0.92
Drug effect prediction by polypharmacology-based interaction profiling. J Chem Inf Model (2011) 0.92
Review of current and "omics" methods for assessing the toxicity (genotoxicity, teratogenicity and nephrotoxicity) of herbal medicines and mushrooms. J Ethnopharmacol (2012) 0.91
Artemisinin--an innovative cornerstone for anti-malaria therapy. Prog Drug Res (2008) 0.90
Omics and its potential impact on R&D and regulation of complex herbal products. J Ethnopharmacol (2012) 0.88
The treatment of eczema with Chinese herbs: a systematic review of randomized clinical trials. Br J Clin Pharmacol (1999) 0.87
Effect of danshen extract on the activity of CYP3A4 in healthy volunteers. Br J Clin Pharmacol (2010) 0.87
Traditional Chinese medicine research in the post-genomic era: good practice, priorities, challenges and opportunities. J Ethnopharmacol (2012) 0.86
Comparison of a protein-level and peptide-level labeling strategy for quantitative proteomics of synaptosomes using isobaric tags. J Proteome Res (2010) 0.86
Establishing an EU-China consortium on traditional Chinese medicine research. Chin Med (2010) 0.85
[Multicenter clinical study about the action of Fuzheng Huayu Capsule against liver fibrosis with chronic hepatitis B]. Zhong Xi Yi Jie He Xue Bao (2003) 0.85
Effects of Ginkgo biloba extract on the pharmacokinetics of bupropion in healthy volunteers. Br J Clin Pharmacol (2009) 0.84
Rapid screening of commercially available herbal products for the inhibition of major human hepatic cytochrome P450 enzymes using the N-in-one cocktail. Xenobiotica (2010) 0.84
Metabolites of ginsenosides as novel BCRP inhibitors. Biochem Biophys Res Commun (2006) 0.84
Retrospective study on Professor Zhongying Zhou's experience in Traditional Chinese Medicine treatment on diabetic nephropathy. J Tradit Chin Med (2013) 0.83
European materia medica in historical texts: longevity of a tradition and implications for future use. J Ethnopharmacol (2010) 0.83
[Investigation on indication of fuzheng huayu capsule against hepatic fibrosis and its non-invasive efficacy evaluation parameters: data analysis of liver biopsy of 50 patients with chronic hepatitis B before and after treatment]. Zhongguo Zhong Xi Yi Jie He Za Zhi (2006) 0.83
Index-ion triggered MS2 ion quantification: a novel proteomics approach for reproducible detection and quantification of targeted proteins in complex mixtures. Mol Cell Proteomics (2010) 0.83
Toxicity and clinical reasonable application of Taoren (Semen Persicae) based on ancient and modern literature research. J Tradit Chin Med (2013) 0.81
Advances in Integrative Nanomedicine for Improving Infectious Disease Treatment in Public Health. Eur J Integr Med (2013) 0.81
A review on natural products for controlling type 2 diabetes with an emphasis on their mechanisms of actions. Curr Diabetes Rev (2013) 0.81
Will the Europe Union's Traditional Herbal Medicinal Products Directive (Directive 2004/24/EC) be against traditional Chinese medicine in EU market? J Evid Based Med (2013) 0.80
Bioactivity-guided fractionation of the volatile oil of Angelica sinensis radix designed to preserve the synergistic effects of the mixture followed by identification of the active principles. J Chromatogr A (2012) 0.78
Application of plant metabonomics in quality assessment for large-scale production of traditional Chinese medicine. Planta Med (2013) 0.77
Antimicrobial activity of Willowherb (Epilobium angustifolium L.) leaves and flowers. Curr Drug Targets (2013) 0.76
Metabolism of hyperforin, the active constituent of St. John's wort, in human liver microsomes. Eur J Pharm Sci (2010) 0.76
Chinese herbal dose in ancient and modern times: a comparative study. J Tradit Chin Med (2013) 0.76
Retinoid and TGF-β families: crosstalk in development, neoplasia, immunity, and tissue repair. Semin Nephrol (2012) 0.85
Recent novel high-tech researches in molecular biology. Biomed Res Int (2015) 0.82
Network pharmacology in traditional chinese medicine. Evid Based Complement Alternat Med (2014) 0.80
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs? Toxicol Lett (2020) 0.75
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs? Toxicol In Vitro (2020) 0.75